HBI Deals+Insights / News
Juvisé, a France-based speciality pharmaceutical company focusing on essential medicines, has secured €550 million in refinancing from investment firm Hayfin. The financing includes €400 million of existing debt and a new €150 million line for capital expenditure, focusing on future M&A opportunities.





